摘要
经肝动脉化疗栓塞术(TACE)联合索拉非尼是目前治疗失去手术机会的中晚期肝细胞癌(HCC)最常用的策略,但具体治疗模式还未形成共识。分析了TACE联合索拉非尼治疗HCC的治疗模式及其有效性和安全性。认为不同的治疗模式均具有其利弊,还需要进行更多的临床研究,为中晚期肝癌患者的治疗提供一定参考。
At present,transarterial chemoembolization（TACE） combined with sorafenib is commonly used for patients with advanced hepatocellular carcinoma（HCC） who have lost the opportunity for surgery,and yet no consensus has been reached on the specific therapeutic paradigm.This article reviews the treatment modes of TACE combined with sorafenib and their effect and safety in the treatment of HCC.It is pointed out that these treatment modes have their own advantages and disadvantages and await further clinical studies,in order to provide a reference for the treatment of patients with advanced HCC.
作者
吴蕾
王甦
WU Lei;WANG Su.(Department of Gastroenterology, Subei People＇s Hospital Affiliated to Medical College of Yangzhou University, Yangzhou, Jiangsu 225001, China)
出处
《临床肝胆病杂志》
CAS
北大核心
2018年第4期867-871,共5页
Journal of Clinical Hepatology
关键词
癌
肝细胞
化学栓塞
治疗性
索拉非尼
综述
carcinoma,hepatocellular
chemoembolization,therapeutic
sorafenib
review
